Ascendis Pharma A (ASND) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

Net selling: insiders sold $873K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$873K net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 0 added, 1 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about ASND filings

Are insiders buying or selling Ascendis Pharma AS (ASND) stock?

Net selling: insiders sold $873K and bought $0 of ASND stock on the open market in the 90 days to Nov 13, 2026, according to SEC Form 4 filings. The largest was Bodenhoff, Mads (SVP & Pao), who sold $811K. The latest filing was on Sep 9, 2026.

Which members of Congress have traded ASND recently?

None. No member of Congress disclosed a ASND trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ASND smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on ASND

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short1 buy · 2 sales
1 of 3 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about ASND filings

Are insiders buying or selling Ascendis Pharma AS (ASND) stock?

Net selling: insiders sold $873K and bought $0 of ASND stock on the open market in the 90 days to Nov 13, 2026, according to SEC Form 4 filings. The largest was Bodenhoff, Mads (SVP & Pao), who sold $811K. The latest filing was on Sep 9, 2026.

Which members of Congress have traded ASND recently?

None. No member of Congress disclosed a ASND trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ASND smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Funds

What funds are doing

11 moves · 6 mo

Buys/Adds$2.1BSells/Trims$33.1M

Buys/Adds (2)

TS
Two Sigma
Q2 2026 13F
$81.6M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
MI
Millennium
Israel Englander · Q2 2026 13F
$71.1M
bought

Sells/Trims (1)

WC
Walleye Capital
Q3 2026 13F
$33.1M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

5 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 5 moves

Other smart money signals

Activist stakes, short interest & more

3 items

FM
FMR LLCLight
FMR LLC filed SC 13G/A on Ascendis Pharma A/S (passive 5.20% stake)
SI
Short Interest ChangeLight
short-volume tape softening: latest 47.4% fell 6.2pp vs 20d avg 53.6%
SI
Short Interest ChangeLight
Short interest fell -10.1% as of 2026-10-15 (twice-monthly FINRA)

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 12, 2026

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 12, 2026

Period ending

Sep 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue

EUR 369.7M

SEC filing

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

$1.42

$0.60 to $2.23

Revenue expected

$410.1M

17 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

+0.27

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	Not on file	No estimate	EUR 369.7MSEC filing	+73.0%from EUR 213.6M
Jun 30, 2026Reported Aug 13, 2026	$3.29est. $0.78	+$2.51beat	EUR 339.3MSEC filing	+114.7%from EUR 158.0M
Mar 31, 2026Reported May 7, 2026	$0.27est. $0.43	-37.21%miss	EUR 250.7MAlpha Vantage	+148.3%from EUR 101.0M
Dec 31, 2025Reported Feb 11, 2026	-$0.55est. -$0.24	-129.17%miss	EUR 245.2MAlpha Vantage	+41.0%from EUR 173.9M
Sep 30, 2025Reported Nov 12, 2025	-$1.00est. -$0.12	-$0.88miss	EUR 213.6MSEC filing	+269.4%from EUR 57.8M
Jun 30, 2025Reported Aug 7, 2025	-$0.93est. -$1.42	+34.51%beat	EUR 158.0MSEC filing	+339.0%from EUR 36.0M
Mar 31, 2025Reported May 1, 2025	-$1.58est. -$1.51	-4.64%miss	EUR 101.0MSEC filing	+5.3%from EUR 95.9M
Dec 31, 2024Reported Feb 12, 2025	-$0.64est. -$1.17	+45.30%beat	EUR 173.9MAlpha Vantage	+26.3%from EUR 137.7M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $264.73
High: $269.85
Low: $258.50
Prev close: $259.28
52-wk high: $282.15
52-wk low: $188.08
Mkt cap: $17.06B
P/E: 19.9x
ROE: +118.8%
Fwd P/E: 21.8x
Beta: 0.48
P/S: 16.3x
P/B: 10.5x
Profit margin: +70.9%
Op margin: +24.7%

Fundamentals

Is the business strong?

Fairly priced and profitable.

Net margin: 70.9%
P/E: 19.87
Forward P/E: 21.79
Market cap: $17.1B

Valuation

P/S16.30
P/B10.54

Quality

Operating margin24.7%
ROE118.8%
ROA9.6%

Growth

Beta0.48

Technicals

Price structure

This stock is in a strong uptrend, and looks overbought after a fast run-up.

Trend

Strong uptrend

85 / 100

RSI 14

75overbought

20D volatility

21%annualized

52-week range

$267.07

$188.08$282.15

20D support

$223.78recent floor

20D resistance

$269.85recent ceiling

Returns

5D +5.4%20D +17.8%60D +2.9%

Price vs moving averages

SMA20 +7.5%SMA50 +10.1%SMA200 +11.5%

Volume pace

0.83xvs prior 20D

News

What the news says

8 articles · 7 days

Coverage is bullish

4 bullish · 4 neutral · 0 bearish

Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
NeutralNov 10
An EU panel backs rare-disease status for a weekly treatment from Ascendis Pharma (ASND).
BullishNov 6
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
BullishNov 6
Ascendis Pharma drug gains orphan designation in EU, nearing approval
BullishNov 6
One holder reports no voting power over a passive stake in Ascendis Pharma (ASND).
NeutralNov 6
A results call is planned for 8 a.m. Eastern on Nov. 12; Ascendis Pharma also plans a business update.
NeutralNov 5
(ASND) Risk Channels and Responsive Allocation
BullishOct 31
Ascendis Pharma A/S (ASND) Seasonal Returns Chart
NeutralOct 30

32 macro signals shaping ASND right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

Ascendis Pharma AS

Smart money at a glance

What do analysts expect?

Questions about ASND filings

Smart money on ASND

Questions about ASND filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Ascendis Pharma AS

Smart money at a glance

What do analysts expect?

Questions about ASND filings

Smart money on ASND

Questions about ASND filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

Ascendis Pharma AS

Overview

Questions about ASND filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.

Ascendis Pharma AS

Overview

Questions about ASND filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Macro

Ask it in Claude or ChatGPT.